| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 6.90 Billion |
| Market Size (2030) | USD 8.44 Billion |
| CAGR (2025 - 2030) | 4.12 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Enbrel Market Analysis
The Enbrel Market size is estimated at USD 6.90 billion in 2025, and is expected to reach USD 8.44 billion by 2030, at a CAGR of 4.12% during the forecast period (2025-2030).
Key drivers, including the surging prevalence of autoimmune diseases, heightened awareness, and advancements in biologic therapies, are poised to fuel the enbrel market's growth in the coming years.
The increasing prevalence of autoimmune disorders, including rheumatoid arthritis and psoriasis, is driving a substantial rise in demand for Enbrel. As a result, the expanding patient base seeking effective biologic treatments is significantly contributing to the growth of the Enbrel market. For instance, according to a study published in the Current Opinion in Immunology in February 2024, the rising incidence of autoimmune diseases, driven by environmental factors such as altered diets, xenobiotics, air pollution, infections, and climate change, is significantly impacting global health. The study reported a 19.1% annual increase in global autoimmune disease incidence and a 12.5% rise in prevalence. As autoimmune conditions continue to rise, the demand for advanced therapies, particularly Enbrel, is set to surge, cementing its role as a pivotal treatment in the burgeoning market.
Similarly, according to a study published in the Annals of Rheumatic Diseases in 2023, the increasing prevalence of ankylosing spondylitis (AS), which affected approximately 0.5% of the global population in 2023, is expected to drive the demand for effective treatments. The chronic pain, stiffness, and potential extra musculoskeletal complications associated with AS further highlight the need for targeted immune-mediated therapies. As a result, the rising incidence of AS is significantly propelling the growth of the Enbrel market, with its proven efficacy in managing such conditions.
Moreover, key players are ramping up their growth strategies in the Enbrel market, a move poised to drive the market's expansion. For instance, in December 2023, Intas Pharmaceuticals Ltd. entered into an exclusive strategic licensing agreement with mAbxience, a Fresenius Kabi majority-owned group, for the development of a biosimilar for Etanercept. This partnership aims to provide a cost-effective alternative to Etanercept, a dimeric fusion protein used in treating autoimmune diseases through its TNF-blocking action. Etanercept-based therapies are set to see a significant boost in availability, thanks to the collaboration, intensifying competition in the enbrel market.
In conclusion, the enbrel market is poised for significant growth driven by the rising prevalence of autoimmune diseases, increasing demand for biologic treatments, and strategic collaborations aimed at expanding the availability of Etanercept-based therapies. However, challenges such as the high cost of treatment and the presence of alternative treatments are anticipated to restrain the growth of the enbrel market.
Enbrel Market Trends
Rheumatoid Arthritis Segment is Expected to Register Considerable Growth Over the Forecast Period
Rheumatoid arthritis (RA) is a chronic autoimmune disorder where the immune system mistakenly attacks the joints, causing inflammation, pain, and potential joint damage. Over time, it can lead to decreased mobility and permanent joint deformities if not managed properly. For many years, Enbrel (etanercept), a TNF inhibitor, has stood as a cornerstone in the treatment of RA. Its efficacy in reducing inflammation, improving physical function, and slowing disease progression has solidified its position in the RA treatment paradigm. Significant factors such as the established efficacy and safety profile, patient convenience, and the increasing combination therapy strategies are expected to boost the growth of the Rheumatoid arthritis segment in the market.
Enbrel's proven efficacy and safety, supported by decades of real-world data and clinical trials, fosters confidence among both physicians and patients, ensuring its ongoing use and preference in the treatment of rheumatoid arthritis (RA). This extensive experience distinguishes Enbrel from newer treatments, which may lack a comparable track record, particularly for specific patient sub-groups with demonstrated positive outcomes.
For instance, according to a study published in the Frontiers in Pharmacology in February 2023, the increasing efficacy and safety profile of etanercept biosimilars, particularly in improving ACR50 response rates at 1 year, has led to greater confidence among clinicians in their use for treating rheumatoid arthritis (RA). With their comparable outcomes in efficacy, safety, and immunogenicity to reference biologics, these biosimilars offer a cost-effective alternative to patients, especially in markets with high financial barriers. This enhanced clinical and economic appeal is expected to drive the growth of the rheumatoid arthritis segment in the Enbrel market.
Similarly, according to a report published in the Arthritis Care and Research in February 2023, the approval of a biosimilar component of etanercept (SB4), provides a cost-effective alternative for treating rheumatoid arthritis (RA), enhancing accessibility and broadening treatment options. With demonstrated clinical equivalence and, in some analyses, superior drug persistence, SB4 offers an appealing choice for healthcare providers and patients. This development is driving growth of the rheumatoid arthritis segment in the Enbrel market by increasing patient adoption and offering a more affordable treatment option, thereby supporting cost containment and expanding market reach.
Moreover, the increasing advancements of enbrel treatments for rheumatoid arthritis are also expected to propel the growth of the segment during the forecast period. For instance, a study published in Modern Rheumatology in March 2024, the introduction of LG Chem’s biosimilar LBEC0101 enhances patient convienience by offering a cost-effective alternative to the reference etanercept product while maintaining equivalent efficacy and safety. Additionally, real-world evidence from the Kyoto University Rheumatoid Arthritis Management Alliance cohort bolsters both physician and patient confidence in adopting biosimilars, thereby enhancing access to advanced treatment options. Consequently, these factors collectively accelerate the growth of the rheumatoid arthritis segment within the enbrel market by expanding patient reach and fostering a more competitive pricing landscape.
In conclusion, the continued evolution of enbrel and its biosimilars, coupled with their proven efficacy, safety, and cost-effectiveness, is driving significant growth in the rheumatoid arthritis segment by enhancing accessibility, treatment options, and patient confidence.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Grow at a Significant Rate in the Market Over the Forecast Period
North America is anticipated to witness growth in the enbrel market owing to factors such as the growing prevalence of autoimmune diseases, and high demand for biologic therapies. For instance, according to a study published by the Arthritis Journal in April 2024, the rising prevalence of psoriatic arthritis, affecting approximately 2.4 million individuals in the United States in 2023, along with an estimated 15% of psoriasis patients remaining undiagnosed, highlights a growing demand for effective treatment options. With over eight million people suffering from psoriasis and around 30% developing psoriatic arthritis, there is a significant patient pool requiring long-term disease management. This increasing patient burden is likely to drive the demand for biologic therapies like Enbrel, positioning it for sustained market growth in the region.
Similarly, in November 2024, the article published in Dermatology and Therapy Journal highlighted a surge in plaque psoriasis cases in North America, with prevalence rates hovering between 1.5% and 3%. It further highlighted that in 2023, 20% of those diagnosed were grappling with moderate to severe forms of the disease, necessitating systemic treatment. This uptick is likely to fuel the demand for potent biologic therapies, notably Enbrel (etanercept). Moreover, due to the persistent nature of psoriasis, long-term management is essential. Enbrel, with its proven efficacy and safety in TNF-α inhibition, has become a favored choice for many prescribers. Consequently, these factors are contributing to the sustained growth of the Enbrel market in North America, as healthcare providers and patients seek reliable long-term treatment solutions.
Additionally, the increasing product approvals in the region are also expected to propel the growth of the market. For instance, in October 2023, the FDA approved Enbrel (etanercept) for the treatment of active juvenile psoriatic arthritis (JPsA) in pediatric patients aged 2 years and older. Safety and efficacy data from adult PsA studies, combined with pharmacokinetic (PK) insights from adults with PsA, rheumatoid arthritis (RA), and psoriasis, as well as from pediatric patients with juvenile idiopathic arthritis (JIA) and psoriasis, favored this decision. This expanded indication is expected to drive Enbrel’s market growth by broadening its patient base and reinforcing its position as a leading treatment in the autoimmune disease space.
In conclusion, the enbrel market in North America is poised for significant growth, driven by the increasing prevalence of autoimmune diseases, rising demand for biologic therapies, expanding treatment indications, and improved healthcare accessibility.
Get Analysis on Important Geographic Markets
Download PDF
Enbrel Industry Overview
The enbrel market is consolidated, with limited number of players in the global market. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some key players in the market are Amgen Inc., Biogen, Cipla, Lupin, and Pfizer Inc.
Enbrel Market Leaders
-
Amgen Inc.
-
Biogen
-
Cipla
-
Lupin
-
Pfizer Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Enbrel Market News
- August 2024: The Centers for Medicare & Medicaid Services (CMS) announced the negotiated prices for the first 10 drugs under the Inflation Reduction Act (IRA), including Stelara (ustekinumab) and Enbrel (etanercept), both of which are expected to face biosimilar competition in the coming years. These drugs, which accounted for approximately USD 50.5 billion in Medicare Part D spending, will see price reductions ranging from 53% to 79%, with Enbrel set at USD 2,335 after a 67% discount.
- May 2024: Lupin, in collaboration with Sandoz Canada, introduced Rymti, its first biosimilar product in the Canadian market, following Health Canada's approval for all therapeutic indications of the reference product Enbrel. Rymti, available in both injectable pre-filled pen and syringe formats, is designed to treat various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis.
Enbrel Industry Segmentation
As per the scope of the report, Enbrel is a biologic medication used to treat autoimmune conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis by blocking tumor necrosis factor (TNF), a protein involved in inflammation. It works by reducing the immune system's overactive response, helping to alleviate pain, swelling, and tissue damage.
The enbrel market is segmented by product type, application, and geography. The product type segment is segmented into branded drugs and biosimilar drugs. The application is segmented into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and others. The other application segment includes juvenile idiopathic arthritis, and non-radiographic axial spondyloarthritis, among others. The geography is further divided into North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. For each segment, the market sizing and forecasts have been done on the basis of value (in USD).
| By Product Type | Branded Drugs | ||
| Biosimilar Drugs | |||
| By Application | Rheumatoid Arthritis | ||
| Psoriatic Arthritis | |||
| Plaque Psoriasis | |||
| Ankylosing Spondylitis | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Enbrel Market Research FAQs
How big is the Enbrel Market?
The Enbrel Market size is expected to reach USD 6.90 billion in 2025 and grow at a CAGR of 4.12% to reach USD 8.44 billion by 2030.
What is the current Enbrel Market size?
In 2025, the Enbrel Market size is expected to reach USD 6.90 billion.
Who are the key players in Enbrel Market?
Amgen Inc., Biogen, Cipla, Lupin and Pfizer Inc. are the major companies operating in the Enbrel Market.
Which is the fastest growing region in Enbrel Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Enbrel Market?
In 2025, the North America accounts for the largest market share in Enbrel Market.
What years does this Enbrel Market cover, and what was the market size in 2024?
In 2024, the Enbrel Market size was estimated at USD 6.62 billion. The report covers the Enbrel Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Enbrel Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Enbrel Industry Report
Statistics for the 2025 Enbrel market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Enbrel analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
